2 results match your criteria: "146995Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital[Affiliation]"
Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer.
J Oncol Pharm Pract
February 2023
Division of Medical Oncology, 146995Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey.
Article Synopsis
- Cyclin-dependent kinase 4/6 inhibitors are new drugs that help treat certain types of metastatic breast cancer and can improve patient outcomes.
- A 56-year-old woman with breast cancer was treated with a drug called ribociclib and developed light patches on her skin (like vitiligo) after six treatment cycles.
- Although the skin changes aren't dangerous, they can be upsetting and make it harder for the patient to stick to her treatment plan.
Vortex keratopathy associated with ribociclib.
J Oncol Pharm Pract
January 2023
Division of Medical Oncology, 146995Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey.
Introduction: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are the new generation drugs that have been started to be used in our clinical practice recently. These drugs have been shown to have better progression-free survival compared to standard therapy in patients with hormone receptor-positive (HR) and human epidermal growth factor receptor 2 (HER-2)-negative breast cancer. The most common side effects of CDK 4-6 inhibitors are neutropenia, nausea, leukopenia, fatigue, and diarrhea.
View Article and Find Full Text PDF